Oligonucleotide Deals Are Up 2400% in 2026 — Here's the Data

Twenty-five oligonucleotide deals closed between January 12 and July 12, 2026 — a +2400% increase over the single deal recorded in the prior six-month window. This is not a statistical anomaly or a one-quarter blip. Large-cap pharma is systematically repricing oligonucleotide platforms upward because three converging forces — validated tissue-targeted delivery, regulatory momentum from recent RNA-based approvals, and thinning small-molecule pipelines in cardio-metabolic and neurology — have made this modality the most aggressively pursued asset class in biopharma BD. If you hold oligonucleotide assets right now, you are sitting on the most in-demand inventory in the industry.

The Data — Oligonucleotide Deal Activity, Period over Period

The magnitude of this shift deserves context. In the prior six-month window, the oligonucleotide space recorded a single transaction — an outlier low that partly reflects deal-timing lumpiness but also reflects the caution that prevailed as several RNAi programs faced delivery-related clinical setbacks in late 2025. The H1 2026 reversal is decisive. Twenty-five transactions in six months puts oligonucleotide licensing 2026 on pace to rival ADC deal volumes from 2023–2024, the last time a single modality dominated BD flow at this intensity.

What's Driving the Trend

Delivery has crossed the credibility threshold. The biggest historical objection to oligonucleotide therapeutics outside liver targets — that extrahepatic delivery remained unproven — has eroded substantially. Arrowhead's TRiM platform, Alnylam's C16 conjugate data in muscle, and multiple GalNAc-next-gen approaches have demonstrated clinically meaningful knockdown in skeletal muscle, CNS, and adipose tissue. When delivery stops being theoretical, the addressable market for an oligo platform expands by an order of magnitude, and Big Pharma valuations follow. That is exactly what the deal data reflects.

Pharma pipeline gaps are acute. Novartis, Lilly, and Sarepta — three of the most active acquirers in this window — share a common strategic problem: their late-stage small-molecule and biologic pipelines in neuromuscular, metabolic, and rare disease are insufficient to sustain growth targets through 2030. Oligonucleotide platforms offer programmability: one delivery chassis can be retargeted across dozens of gene targets, giving the buyer a pipeline-in-a-platform rather than a single-asset bet. That programmability premium is why total deal values are stretching into the multi-billion-dollar range.

Regulatory clarity is accelerating timelines. The FDA's evolving guidance on oligonucleotide CMC, including updated expectations around impurity profiling for modified nucleotides, has reduced manufacturing risk perception. Combined with multiple precedent approvals (inclisiran, patisiran, vutrisiran, eplontersen), regulatory derisking has lowered the discount rate that pharma applies to oligo assets in DCF models. The result: higher upfronts, fatter milestones, and a willingness to pay for earlier-stage platforms that would have been considered premature 18 months ago.

Notable Deals

Arrowhead–Sarepta ($500M upfront / $10B TDV) is the headline transaction and the clearest signal of where the market is headed. Sarepta paid a $500M upfront — among the largest non-acquisition upfronts in 2026 — for access to Arrowhead's muscle-targeted RNAi platform. The $10B total deal value implies Sarepta is modeling multiple programs across its neuromuscular franchise, not a single-asset license. This deal sets the ceiling for oligonucleotide platform licensing 2026 and will anchor every comp table for the next 12 months. If you are negotiating an oligo deal right now, your counterpart has already seen this number.

Argo Biopharma–Novartis ($160M upfront) is notable because Argo is a relatively early-stage company. A $160M upfront for what is likely preclinical-to-Phase-1 assets signals that Novartis is paying a significant access premium to secure platform optionality before competitors lock up remaining targets. Check how this compares to historical norms using our Deal Benchmarks — the median upfront for preclinical-stage oligonucleotide deals in 2024 was roughly $30M–$50M. Novartis paid 3–5x that.

Ascidian–Lilly ($1.9B TDV) is the RNA editing play. Ascidian's ADAR-based approach represents a distinct mechanism within the oligonucleotide modality — programmable RNA editing rather than knockdown. Lilly's willingness to underwrite a $1.9B TDV for this platform validates that pharma is not just buying into siRNA and ASOs; the entire oligonucleotide modality spectrum, including emerging approaches like RNA editing, is being bid up.

Silence Therapeutics–Hansoh ($16M upfront) stands in stark contrast. The modest upfront likely reflects a regional (China-focused) license scope and narrower target access. It is a useful data point for BD teams to calibrate: geography and exclusivity scope still create 30x valuation differentials within the same modality window.

What This Means for BD Teams Right Now

This is unequivocally a seller's market for oligonucleotide assets. Twenty-five deals in six months means at least a dozen pharma BD teams are actively competing for a finite pool of credible oligo platforms and programs. If you are a biotech with a differentiated delivery technology, validated knockdown data in an extrahepatic tissue, or an RNA editing platform with in vivo proof-of-concept, you have leverage that did not exist 12 months ago. Use it.

Tactically, licensors should be pushing for higher upfronts and more aggressive milestone structures. The Arrowhead–Sarepta deal demonstrates that pharma will pay $500M upfront for the right platform — and the Argo–Novartis deal shows this willingness extends to earlier-stage assets. Run your term sheet through the Ambrosia Deal Calculator to see where your proposed economics sit relative to these recent comps.

For buyers, speed matters more than perfection. The window to acquire best-in-class oligo platforms at 2024 valuations is closed. Every month of delay increases the probability that your target licensor receives a competing term sheet — or gets acquired outright. BD teams should be pre-positioning with governance and diligence readiness to compress timelines from LOI to signed deal. The deals that are not getting done right now are the ones stuck in 90-day diligence cycles while a competitor moves in 45.

Deal structures are shifting toward platform access. Single-target licenses are losing favor on both sides. Licensors prefer multi-target structures because they capture more value per transaction. Licensees prefer them because programmable platforms justify the upfront premium — you are buying a franchise, not a molecule. Expect to see more deals structured with initial target commitments plus options on additional targets, with escalating option exercise fees.

One structural trend worth monitoring: co-development and co-commercialization rights are appearing more frequently in oligonucleotide term sheets than in comparable ADC or cell therapy deals. Licensors with commercial-stage infrastructure (like Arrowhead and Alnylam) are increasingly retaining U.S. or ex-China rights rather than granting global exclusivity. BD teams should model split-territory structures as a baseline scenario.

Benchmark your deal against current market rates using the Ambrosia calculator. The oligonucleotide deal landscape has repriced faster than any modality since ADCs in 2023. If your internal comps are older than six months, they are wrong.